Related Experiment Video
Updated: Jun 16, 2025

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy
Published on: January 31, 2025
GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD
Qiang Zhang1, Jingyuan Wang2, Xiaojin Hu3
1Department of Gastroenterology, Yancheng Third People's Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University), Yancheng, Jiangsu Province 224000, PR China.
Background:
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of cirrhosis and a major risk factor for hepatocellular carcinoma and liver-related death. Diabetes medications have been studied as potential treatments for NAFLD. Glucagon-like peptide-1 agonists (GLP-1RAs) have been rarely reported in the treatment of NAFLD alone as an anti-diabetic drug, and its specific mechanism of action is unknown. We investigated whether the therapeutic effect of liraglutide (LRG, a representative drug of GLP-1RAs) on hepatic steatosis is related to regulating lipid metabolism and enhancing autophagy in the hepatocytes.
Methods:
We examined the effect of LRG on fat accumulation in fatty hepatocytes, and discussed its effects on enzymes related to lipid metabolism and autophagy. Meanwhile, knockdown of SIRT1 in free fatty acids(FFA)-treated cells was used to detected the influence of LRG on lipid metabolism and autophagy by regulating of AMPK/SIRT1 signaling.
Results:
Our findings showed that free fatty acids (FFA) induced hepatocyte steatosis, which was significantly reversed by LRG. Meanwhile, LRG significantly regulated the expression of hepatocyte lipogenesis and cytosolic lipolysis-related proteins (FAS, ACC1, ATGL, HSL, LAL). Furthermore, LRG enhanced FFA-induced suppression of autophagy and SIRT1 expression, reducing intracellular lipid accumulation. It is evident that LRG regulates lipid metabolism and induces autophagy in an (AMPK)-dependent manner. Moreover, SIRT1 knockdown inhibited the autophagy-inducing and lipid-lowering effects of LRG.
Conclusion:
GLP-1RAs may lower hepatic steatosis by regulating lipid metabolism and enhancing autophagy in an AMPK/SIRT1-dependent manner, providing a new target for the treatment of NAFLD.
Insights
Liraglutide reverses fatty liver in hepatocytes by regulating lipid metabolism and enhancing autophagy. This action occurs through the AMPK/SIRT1 pathway, offering a new therapeutic target for non-alcoholic fatty liver disease.
Area of Science:
- Hepatology
- Molecular Biology
- Endocrinology
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a significant cause of cirrhosis and liver-related mortality.
- Current treatments for NAFLD are limited, necessitating exploration of novel therapeutic agents.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) show potential for NAFLD treatment, but their mechanisms require elucidation.
Purpose of the Study:
- To investigate the therapeutic effect of liraglutide (LRG), a GLP-1RA, on hepatic steatosis.
- To determine if LRG's effect on NAFLD involves regulating lipid metabolism and enhancing autophagy in hepatocytes.
- To elucidate the specific molecular pathways, including AMPK/SIRT1 signaling, involved in LRG's action.
Main Methods:
- Examined LRG's effect on fat accumulation in fatty hepatocytes.
- Assessed LRG's impact on enzymes regulating lipid metabolism and autophagy.
- Utilized SIRT1 knockdown in free fatty acid (FFA)-treated cells to investigate LRG's mechanism via AMPK/SIRT1 signaling.
Main Results:
- LRG significantly reversed FFA-induced hepatocyte steatosis.
- LRG modulated the expression of key proteins involved in lipogenesis and lipolysis (FAS, ACC1, ATGL, HSL, LAL).
- LRG enhanced autophagy, increased SIRT1 expression, and reduced lipid accumulation in an AMPK-dependent manner, with SIRT1 knockdown diminishing these effects.
Conclusions:
- GLP-1RAs, like LRG, may treat hepatic steatosis by modulating lipid metabolism and autophagy.
- The AMPK/SIRT1 pathway is crucial for the therapeutic effects of LRG on NAFLD.
- These findings suggest GLP-1RAs as a promising therapeutic strategy for NAFLD.
More Related Videos
09:41Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
04:14Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
PI3K/mTOR/AKT Signaling Pathway
Regulation of Food Intake
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
cAMP-dependent Protein Kinase Pathways
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...